KRAS mutant bowel cancers segregate into two distinct subgroups

被引：0

作者：

Borowsky, J. ^{[1
,2
,3
]}

Su, C. ^{[1
]}

Fennell, L. ^{[1
]}

Burge, M. ^{[4
]}

Liu, J. ^{[2
]}

Costa, A. Dias ^{[8
]}

Ogino, S. ^{[9
,10
,11
]}

Mckeone, D. ^{[2
]}

Olsen, K. ^{[2
]}

Badshah, J. ^{[2
]}

Bond, C. ^{[2
]}

Nowlan, B. ^{[2
]}

Tria, S. ^{[2
]}

Laki, V. ^{[2
]}

Walker, N. ^{[6
]}

Brown, I. ^{[6
]}

Bettington, M. ^{[6
]}

Leggett, B. ^{[2
,5
]}

Whitehall, V. ^{[2
,7
]}

机构：

[1] Queensland Hlth, Pathol Queensland, Brisbane, Qld, Australia

[2] QIMR Berghofer Med Res Inst, Brisbane, Qld, Australia

[3] Univ Queensland, Sch Med, Brisbane, Australia

[4] Royal Brisbane & Womens Hosp, Dept Med Oncol, Herston, Qld, Australia

[5] Royal Brisbane & Womens Hosp, Dept Gastroenterol, Herston, Qld, Australia

[6] Envoi Pathol, Brisbane, Australia

[7] Queensland Hlth, Conjoint Internal Med Lab, Pathol Queensland, Brisbane, Qld, Australia

[8] Dana Farber Canc Inst, Boston, MA USA

[9] Harvard Med Sch, Dept Pathol, Program MPE Mol Pathol Epidemiol, Brigham & Womens Hosp, Boston, MA USA

[10] Broad Inst MIT & Harvard, Cambridge, MA USA

[11] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2023年 / 38卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

239

引用

页码：28 / 29

页数：2

共 50 条

[31] A proteomic and phosphoproteomic landscape of KRAS mutant cancers identifies combination therapies
Liu, Zhiwei
Liu, Yingluo
Qian, Lili
Jiang, Shangwen
Gai, Xiameng
Ye, Shu
Chen, Yuehong
Wang, Xiaomin
Zhai, Linhui
Xu, Jun
Pu, Congying
Li, Jing
He, Fuchu
Huang, Min
Tan, Minjia
MOLECULAR CELL, 2021, 81 (19) : 4076 - +
[32] Molecular and clinicopathologic evidence of heterogeneity in KRAS-mutant colon cancers
Popovici, Vlad Calin
Budinska, Eva
Tejpar, Sabine
d'Ario, Giovanni
Di Narzo, Antonio Fabio
Hodgson, John Graeme
Roth, Arnaud
Bosman, Fred
Delorenzi, Mauro
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[33] Receptor tyrosine kinases, not KRAS, activate PI3K in KRAS mutant colorectal cancers
Ebi, Hiromichi
Corcoran, Ryan B.
Singh, Anurag
Chen, Zhao
Song, Youngchul
Lifshits, Eugene
Ryan, David P.
Meyerhardt, Jeffrey A.
Benes, Cyril
Settleman, Jeffrey
Cantley, Lewis C.
Wong, Kwok-Kin
Engelman, Jeffrey A.
CANCER RESEARCH, 2011, 71
[34] KRAS mutant lung adenocarcinoma is associated with distinct mutational signature profiles
Woodhouse, Laura
Hawari, Aliah
Gruber, Andreas
Lindsay, Colin
Wedge, David
CANCER RESEARCH, 2024, 84 (06)
[35] Viral internal ribosome entry site structures segregate into two distinct morphologies
Beales, LP
Holzenburg, A
Rowlands, DJ
JOURNAL OF VIROLOGY, 2003, 77 (11) : 6574 - 6579
[36] Zoledronic acid enhances the efficacy of the MEK inhibitor trametinib in KRAS mutant cancers
Dai, Xinyu
Xia, Hongwei
Zhou, Sheng
Tang, Qiulin
Bi, Feng
CANCER LETTERS, 2019, 442 : 202 - 212
[37] The genomic landscape of Kras mutant genetically engineered mouse models of human cancers
Chung, Wei-Jen
Daemen, Anneleen
Long, Jason
Cheng, Jason
Tran, Chris
Modrusan, Zora
Foreman, Oded
Junttila, Melissa
CANCER RESEARCH, 2016, 76
[38] Searching for treatments for non-G12C-KRAS mutant cancers
Christina Guo
Udai Banerji
British Journal of Cancer, 2021, 125 : 625 - 626
[39] Searching for treatments for non-G12C-KRAS mutant cancers
Guo, Christina
Banerji, Udai
BRITISH JOURNAL OF CANCER, 2021, 125 (05) : 625 - 626
[40] Kras mutant genetically engineered mouse models of human cancers are genomically heterogeneous
Chung, Wei-Jen
Daemen, Anneleen
Cheng, Jason H.
Long, Jason E.
Cooper, Jonathan E.
Wang, Bu-er
Tran, Christopher
Singh, Mallika
Gnad, Florian
Modrusan, Zora
Foreman, Oded
Junttila, Melissa R.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2017, 114 (51) : E10947 - E10955

← 1 2 3 4 5 →